This is a news story, published by CU Anschutz Newsroom, that relates primarily to the Journal of Infectious Diseases news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CU Anschutz Newsroom, you can click here:
more news from CU Anschutz NewsroomOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
intravenous remdesivir. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest remdesivir treatment news, Pharmacokinetic studies news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
antiviral medicationCU Anschutz Newsroom
•
89% Informative
A new study provides important insights into the pharmacokinetics and safety of intravenous remdesivir in treating the SARS-CoV-2 coronavirus in pregnant women.
The study, published in the Journal of Infectious Diseases , is the first pharmacokinetic study to be published on a COVID-19 therapy.
The U.S. Food and Drug Administration approved a supplemental new drug application.
VR Score
93
Informative language
97
Neutral language
24
Article tone
formal
Language
English
Language complexity
84
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
5
Affiliate links
no affiliate links